TY - JOUR
T1 - What over the counter (OTC) products have been evaluated for anxiety in adults aged 18–60? A scoping review
AU - Frost, Rachael
AU - Uddin, Sayem
AU - Mathew, Silvy
AU - Thomas, Verity
AU - Salame, Adriana
AU - Bhamra, Sukvinder Kaur
AU - Bazo-Alvarez, Juan Carlos
AU - Bhanu, Cini
AU - Heinrich, Michael
AU - Walters, Kate
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Background: Anxiety symptoms and disorders are common in the UK. Whilst waiting for, or alongside, treatments such as anxiolytics or psychological therapies, people often self-manage anxiety symptoms with products purchased over-the-counter (OTC), such as herbal medicines or dietary supplements. However, the evidence for these products is often presented across different reviews and is not easy for patients or healthcare professionals to compare and understand. Aims: To determine the nature and size of the evidence base available for these products. Methods: A scoping review. CENTRAL, MEDLINE, EMBASE, PsycInfo, and AMED (inception—Dec 2022) were searched for RCTs assessing OTC products in people aged 18–60 with symptoms or a diagnosis of anxiety. Results: In total 69 papers assessing a range of products were found, which mostly focussed on kava, lavender, saffron, probiotics, Galphimia glauca and valerian. Studies used varying dosages. Compared to herbal medicine studies, there were much fewer dietary supplement studies and homeopathic remedy studies, despite some of use of these by the general public. Conclusion: Future research needs to investigate commonly used but less evaluated products (e.g. chamomile, St John’s Wort) and to evaluate products against or alongside conventional treatments to better reflect patient decision making.
AB - Background: Anxiety symptoms and disorders are common in the UK. Whilst waiting for, or alongside, treatments such as anxiolytics or psychological therapies, people often self-manage anxiety symptoms with products purchased over-the-counter (OTC), such as herbal medicines or dietary supplements. However, the evidence for these products is often presented across different reviews and is not easy for patients or healthcare professionals to compare and understand. Aims: To determine the nature and size of the evidence base available for these products. Methods: A scoping review. CENTRAL, MEDLINE, EMBASE, PsycInfo, and AMED (inception—Dec 2022) were searched for RCTs assessing OTC products in people aged 18–60 with symptoms or a diagnosis of anxiety. Results: In total 69 papers assessing a range of products were found, which mostly focussed on kava, lavender, saffron, probiotics, Galphimia glauca and valerian. Studies used varying dosages. Compared to herbal medicine studies, there were much fewer dietary supplement studies and homeopathic remedy studies, despite some of use of these by the general public. Conclusion: Future research needs to investigate commonly used but less evaluated products (e.g. chamomile, St John’s Wort) and to evaluate products against or alongside conventional treatments to better reflect patient decision making.
KW - Anxiety
KW - dietary supplements
KW - herbal medicine
KW - homeopathy
KW - over-the-counter
UR - https://www.scopus.com/pages/publications/85205359409
U2 - 10.1080/09638237.2024.2408231
DO - 10.1080/09638237.2024.2408231
M3 - Review article
AN - SCOPUS:85205359409
SN - 0963-8237
VL - 34
SP - 695
EP - 715
JO - Journal of Mental Health
JF - Journal of Mental Health
IS - 6
ER -